Author Archives: Megan Thomas

Machine learning concept
#Artificial intelligence (AI) #Drug discovery #Machine learning #VeriSIM Life

The impact of AI and ML on the future of drug discovery  

Over the past several years, Dr Jo Varshney, Founder of VeriSIM Life, has front-led numerous collaborative engagements with a host of biopharma companies, government agencies, academic/medical institutes and industry innovators. Here, she discusses with DDW’s Megan Thomas the impact of AI and ML on the drug discovery process.   MT:… Read More

#Exclusive Content #Opinion

#Cancer research #DDW Turning Science into Business Summit #Drug discovery #Oncology

New DDW Highlights podcast: 23 October 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  To celebrate DDW’s first Turning Science into Business Summit on ‘Cancer research… Read More

#News

#DDW Highlights podcast

DDW Highlights: 23 October 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  To celebrate DDW’s first Turning Science into Business Summit on ‘Cancer research… Read More

#Podcasts

HIV test
#FDA #HIV #Monoclonal antibodies #Theratechnologies

Results from HIV mAB intramuscular administration study 

Theratechnologies, a biopharmaceutical company focused on the development and commercialisation of innovative therapies, has announced results from a study evaluating an intramuscular (IM) method of administration for Trogarzo (ibalizumab-uiyk), a monoclonal antibody antiretroviral therapy (ART) for the treatment of heavily treatment-experienced adults with multidrug-resistant (MDR) HIV-1 infection failing their… Read More

#News

#etherna #mRNA #Novalis

New leadership for mRNA company etherna  

etherna, an mRNA/LNP technologies company, has announced that Bernard Sagaert has been confirmed as Chief Executive Officer. At the same time Marijn Dekkers, an existing Board Member representing investor Novalis LifeSciences LLC, has been appointed Chairman of the Board.  Sagaert’s appointment follows an interim 12-month period during… Read More

#Business & Investment #News

#Clinical trials #Deep learning #Immunotherapy #Oncology #Start-ups

New podcast: Drug discovery success stories

This is the latest episode of the free DDW narrated podcast, “Drug discovery success stories”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Global pharma start-up success stories”, and “Excitement at rectal… Read More

#News

#Narrated podcasts

Drug discovery success stories

This is the latest episode of the free DDW narrated podcast, “Drug discovery success stories”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Global pharma start-up success stories”, and “Excitement at rectal… Read More

#Podcasts

#Animal testing #ApconiX #Assays #FDA #Preclinical development

New podcast explores Sengenics’ i-Ome Discovery Microarrays

The latest sponsored DDW Sitting Down With podcast features Professor Jonathan Blackburn, Chief Scientific Officer of Sengenics, who discusses the advantages of functional protein microarrays, challenges to overcome for biomarker discovery, Sengenics’ new i-Ome Discovery… Read More

#News

#Clinical trial #Clinical trials #Drug development #Drug discovery #Phase I trial

New podcast: DDW Highlights 17 October 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The buzz with week has been around Phase I trials, with new… Read More

#News

#DDW Highlights podcast

DDW Highlights: 17 October 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The buzz with week has been around Phase I trials, with new… Read More

#Podcasts

#AI #BioMap #Biotherapeutics #Collaboration #Sanofi

Collaboration to develop AI modules for biotherapeutics 

BioMap has entered a strategic collaboration with Sanofi to co-develop AI modules for biotherapeutic drug discovery, leveraging BioMap’s AI platform.  Traditional AI methods require vast amounts of labeled data to make accurate predictions. However, in life science, labeled data are often in short supply. BioMap’s foundational models… Read More

#News

#AAV #AskBio #Duchenne muscular dystrophy #Gene editing #Giant axonal neuropathy #Haemophilia #Pompe disease

Podcast: The evolution and future of gene therapy

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dr… Read More

#News

#In Conversation Series

The evolution and future of gene therapy

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dr… Read More

#Podcasts

#Automation #Cell and gene therapy #CTMC #MD Anderson Cancer Center #National Resilience #ScaleReady

CGT partnership to automate for greater patient accessibility 

ScaleReady and CTMC, a joint venture between National Resilience and MD Anderson Cancer Center, have partnered to help lessen the manufacturing barriers holding back life-saving cell and gene therapies (CGTs) from reaching more patients by integrating automation tools.   The agreement will enable CTMC to strategically scale… Read More

#Business & Investment #News

#Biotechnology #Funding #Immunology / Virology & Vaccines #MinervaX

Funding to advance maternal vaccine against streptococcus 

MinervaX, a Danish biotechnology company developing a novel, prophylactic vaccine against Group B streptococcus (GBS), has announced the completion of €54 million upsized financing.   GBS is a leading cause of life-threatening infections in newborns as well as adverse pregnancy outcomes such as preterm delivery and stillbirths. Read More

#News